Peptipedia
Anti-AgingIn Clinical TrialsClinical Trials

NAD+ Precursors

Also known as NMN, NR, Nicotinamide Riboside, Nicotinamide Mononucleotide

While not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.

Available as supplements - Clinical trials ongoing
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

NMN: 250-1000mg daily; NR: 300-1000mg daily

Frequency

Once daily, consistent timing

Duration

Ongoing supplementation

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: NMN: 250-1000mg daily; NR: 300-1000mg daily via Oral (capsules, sublingual), Once daily, consistent timing. Dose range: 250-1000 mg daily. Duration: Ongoing supplementation.

Timing & Administration

Administer via Oral (capsules, sublingual). Frequency: Once daily, consistent timing.

Mechanism of Action

NMN and NR are converted to NAD+ in cells. NAD+ is essential for mitochondrial function, DNA repair, and sirtuin enzyme activity. Sirtuins regulate metabolism, stress response, and longevity pathways. NAD+ levels decline with age.

Research Summary

Evidence level: clinical trials. Clinical status: Available as supplements - Clinical trials ongoing.

Side Effects & Safety

Important Warnings

  • Theoretical cancer concerns with chronic use
  • NR has GRAS status.
Diarrhea (rare)
nausea (rare)
skin rashes (rare)
does not cause flushing like niacin

References

No references available.

Related Peptides

Browse all →
DSIPAnti-Aging

A peptide studied for its ability to promote deep sleep and modulate stress hormones.

View profile
HumaninAnti-Aging

A mitochondria-derived peptide discovered for its neuroprotective effects against Alzheimer's-related toxicity.

View profile
SS-31Anti-Aging

A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome in September 2025.

View profile